Thoroughbred Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-17,917
| Closed | -$275K | – | 696 |
|
|
2025
Q1 | $275K | Hold |
17,917
| – | – | 0.02% | 575 |
|
|
2024
Q4 | $394K | Sell |
17,917
-715
| -4% | -$15.7K | 0.02% | 475 |
|
|
2024
Q3 | $335K | Buy |
18,632
+1,040
| +6% | +$18.7K | 0.02% | 494 |
|
|
2024
Q2 | $285K | Buy |
17,592
+2,200
| +14% | +$35.6K | 0.02% | 515 |
|
|
2024
Q1 | $217K | Sell |
15,392
-2,408
| -14% | -$33.9K | 0.02% | 430 |
|
|
2023
Q4 | $185K | Sell |
17,800
-1,440
| -7% | -$15K | 0.01% | 580 |
|
|
2023
Q3 | $196K | Sell |
19,240
-16,070
| -46% | -$164K | 0.02% | 552 |
|
|
2023
Q2 | $265K | Sell |
35,310
-69,067
| -66% | -$518K | 0.03% | 351 |
|
|
2023
Q1 | $923K | Sell |
104,377
-52
| -0% | -$460 | 0.14% | 164 |
|
|
2022
Q4 | $952K | Buy |
104,429
+79,219
| +314% | +$722K | 0.16% | 150 |
|
|
2022
Q3 | $203K | Buy |
+25,210
| New | +$203K | 0.04% | 347 |
|